Glycominds Ltd.

1, Yodfat Street
71291 Lod

Phone: +972 8 9181080
Fax: +972 8 9181081


Company Contacts
Department/ Name Address

Michal B Lichter, B.Sc. IBDX(TM) Product Manager 1, Yodfat St., Lod, 71291, Israel
Company Figures
Year of foundation 1999
Area of business Diagnostics

Company Profile

Glycominds Ltd.
Glycominds Ltd. provides high value tests for differential diagnostics and for disease stratification of Crohn’s disease and Ulcerative Colitis. The IBDX(TM) panel, a series of simple blood tests for chronic intestinal diseases is in the market and additional glycan-probes for crohn’s Colitis and UC and for IBS are under development.
Our pipeline includes blood tests for Multiple Sclerosis and additional tests for autoimmune diseases. Leveraging our proprietary GlycoChip technology, we are discovering and validating novel glycan markers keeping a continuous stream of high value products.

Our products:

IBDX(TM) ELISA-The IBDX(TM) panel is the most reliable and cost-effective ELISA diagnostics for Crohn’s Disease patients with improved sensitivity and specificity. ALCA and ACCA our novel suger-antigens together with improved Glycominds’ ASCA-The gASCA, provide us with superior tests in standardized enzyme immunoassay formats enabling advanced diagnosing of IBD patients. Kits are available. Additional glycan-probes for Crohn’s Colitis and Ulcerative Colitis for disease stratification and Irritable Bowel Syndrome (IBS) are under development.

gMS(TM)- The gMS(TM) is a multi-analyte test designed to provide diagnostic and prognostic value for multiple sclerosis patients. The gMS(TM)- An Early Diagnosis and Disease Activity Predictor assay is in its external validation phase via several clinical study.

GLW Gesellschaft für Laborbedarf mbH
GLS Corporation
Glorious Enterprises
Gloria Med S.p.A.

GlysBy s.n.c.
GMC-I Gossen-Metrawatt GmbH
GMI, Global Medical Instrumentation
GML Aktiengesellschaft für Medizintechnik und Logistikmanagement